Skip to main content
Erschienen in: Supportive Care in Cancer 4/2019

27.09.2018 | Original Article

Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients

verfasst von: Sam E. Grigg, Patrick Date, Zoe Loh, Ortis Estacio, Douglas F. Johnson, Eliza A. Hawkes, Andrew Grigg

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is a paucity of data regarding the utility of routine urine cultures in adults with febrile neutropenia (FN) without urinary symptoms receiving protocolised antibiotics. This is reflected by inconsistent recommendations in international and regional FN guidelines. We addressed this issue by retrospectively reviewing the impact of routine urine cultures on antibiotic management in haematology cancer inpatients at a tertiary hospital.

Methods

All haematology inpatients over a 5-year period (2011–2015) were retrospectively reviewed for episodes of FN (neutrophil count < 0.5 × 109/L and fever > 37.5 °C). For each episode, demographic data, urinary tract symptoms and signs (absence of which was termed ‘asymptomatic’), urinalysis and urine culture results, antibiotic therapy and duration, and patient outcomes were collected. A urine culture was considered positive if > 105 colony forming units (CFU)/L were detected. Empiric antibiotic therapy for FN consisted of intravenous piperacillin/tazobactam in stable patients, with the addition of vancomycin and a single dose of gentamicin if systemically compromised.

Results

Four hundred and thirty-three episodes of FN were identified in 317 patients. Urine cultures were performed in 362 (84%) episodes. Cultures were positive in 9 of 48 (19%) symptomatic episodes versus 8 of 314 (2.5%) asymptomatic episodes (RR = 7.4, p < 0.0001). A change in antibiotic management due a positive urine culture occurred in only 5 episodes (1.4%): 3 of 48 (6.3%) symptomatic and 2 of 314 (0.6%) asymptomatic episodes respectively (RR = 9.8, p = 0.01).

Conclusion

Routine urine cultures in FN patients without urinary symptoms who are already receiving protocolised broad spectrum antibiotics rarely impact subsequent antibiotic management.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of Americaa (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of Americaa (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431CrossRefPubMed
2.
Zurück zum Zitat Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111–v1v8CrossRefPubMed Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111–v1v8CrossRefPubMed
3.
Zurück zum Zitat Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39:S49–S52CrossRefPubMed Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39:S49–S52CrossRefPubMed
9.
Zurück zum Zitat Chan W (2016) Urine cultures. In: Leber A (ed) Clinical microbiology procedures handbook, 4th edn. ASM Press, Washington 3.12.6 Chan W (2016) Urine cultures. In: Leber A (ed) Clinical microbiology procedures handbook, 4th edn. ASM Press, Washington 3.12.6
12.
Zurück zum Zitat Wong M, Barqasho B, Öhrmalm L, Tolfvenstam T, Nowak P (2013) Microbial translocation contribute to febrile episodes in adults with chemotherapy-induced neutropenia. PLoS One 8:e68056CrossRefPubMedPubMedCentral Wong M, Barqasho B, Öhrmalm L, Tolfvenstam T, Nowak P (2013) Microbial translocation contribute to febrile episodes in adults with chemotherapy-induced neutropenia. PLoS One 8:e68056CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Steinrucken J, Pabst T, Zimmerli S, Marschall J (2016) Low impact of urine cultures as a diagnostic tool in patients with neutropenic fever. Infect Dis (Lond) 48:872–874CrossRef Steinrucken J, Pabst T, Zimmerli S, Marschall J (2016) Low impact of urine cultures as a diagnostic tool in patients with neutropenic fever. Infect Dis (Lond) 48:872–874CrossRef
14.
Zurück zum Zitat Hooton TM, Roberts PL, Cox ME, Stapleton AE (2013) Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 369:1883–1891CrossRefPubMedPubMedCentral Hooton TM, Roberts PL, Cox ME, Stapleton AE (2013) Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 369:1883–1891CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Weinkove R, Clay J, Wood C (2013) Temperature management in haematology patients with febrile neutropenia: a practice survey. N Z Med J 126:62–73PubMed Weinkove R, Clay J, Wood C (2013) Temperature management in haematology patients with febrile neutropenia: a practice survey. N Z Med J 126:62–73PubMed
16.
Zurück zum Zitat Frimodt-Møller N (2002) Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 19:546–553CrossRefPubMed Frimodt-Møller N (2002) Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 19:546–553CrossRefPubMed
17.
Zurück zum Zitat Klaassen IL, de Haas V, van Wijk JA, Kaspers GJ, Bijlsma M, Bokenkamp A (2011) Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 56:868–870CrossRefPubMed Klaassen IL, de Haas V, van Wijk JA, Kaspers GJ, Bijlsma M, Bokenkamp A (2011) Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 56:868–870CrossRefPubMed
Metadaten
Titel
Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients
verfasst von
Sam E. Grigg
Patrick Date
Zoe Loh
Ortis Estacio
Douglas F. Johnson
Eliza A. Hawkes
Andrew Grigg
Publikationsdatum
27.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4476-7

Weitere Artikel der Ausgabe 4/2019

Supportive Care in Cancer 4/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.